SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2902<By the end of the conference call, a 093 plus ruxolitinib combo, lymphoma, sBiotech Jim-8/2/2013
2901PARP inhibitor... a major Agouron project, the second arm of the magic bulletscaram(o)uche-8/2/2013
2900I keep forgetting about the CLVS PARP inhibitor.rkrw-8/2/2013
2899oooops, made my list due to the PARP inhibitor and its combo testing with PI3K iscaram(o)uche-8/2/2013
2898Clovis is an EGFR. TGTX is in P1. rkrw-8/2/2013
2897By the end of the conference call, a 093 plus ruxolitinib combo, lymphoma, seemescaram(o)uche-8/1/2013
2896Cool. There's a study around here someplace, maybe the indications-cancer tscaram(o)uche-8/1/2013
2895"we do have interest in moving 110 forward in inflammation" "datscaram(o)uche-8/1/2013
2894And the undisclosed mechanism for the other new compound is PI3Kinase delta! PaBiotech Jim-8/1/2013
2893Well, we get both.... "A second JAK1 inhibitor, INCB47986, is currently inscaram(o)uche-8/1/2013
2892Thanks, Sales! That would make the B cell bit a tad more straight-forward. ;-)scaram(o)uche17/29/2013
2891Rick, additional speculation: oncology.healthace.com sales Incyte: Undisclosesoftware salesperson27/29/2013
2890Hi Rick- I will have to think about this one for a few days, as I am in the mBiotech Jim17/29/2013
2889Leuk Res. 2013 May;37(5):573-9. doi: 10.1016/j.leukres.2013.02.001. Epub 2013 Fescaram(o)uche-7/29/2013
2888"Rank" 3 is an update today, not an incy-sponsored trial...... clinicscaram(o)uche-7/29/2013
2887Cited by Creelan et al., this addresses your question in spirit only (CTLA4 blocscaram(o)uche-7/24/2013
2886<i>as 1-methyl-DL- tryptophan is likely a micromolar inhibitor, and the INscaram(o)uche-7/24/2013
2885INCB040093...... google knows next to nothing (there's funding for phase scaram(o)uche17/24/2013
2884$33M in 2Q13 ex-US sales (mostly from EU): DewDiligence_on_SI-7/23/2013
2883Does NVS give the $$$ for Jakafi sales in EU? Thanks! WIDWatch_It_Drop-7/23/2013
2882enrollment opens for "BEYOND".scaram(o)uche-7/2/2013
2881>> the psoriasis phase I is "complete" << Phase 2. Sorryscaram(o)uche-6/29/2013
2880Awkward. Meanwhile, 110 et al. just keep on moving. Tofacitinib ads are all ovscaram(o)uche-6/29/2013
2879I do recall the Sepracor antihistamine drug that ultimately got derailed becauseBiomaven-6/29/2013
2878"Are they basically saying that the metabolite is the product?" Not qtommysdad-6/28/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News